期刊文献+

心房颤动的药物治疗进展 被引量:1

Progress of Pharmalogical Therapy for Atrial Fibrillation
下载PDF
导出
摘要 药物治疗一直是心房颤动处理的基本和主要方法,传统上分为心室率控制、节律控制和抗凝三个方面。合理和规范化联合用药对于控制心房颤动症状以及并发的心力衰竭、脑梗死是十分重要的。此外,为了优化药物或其他高级方案的正确选用,心房颤动新的分类、心电图诊断时的疑难要点、美国脑卒中风险评分CHADS2和欧洲CHA2DS2VASc的异同是研究的重点。 Pharmalogicacol therapy has been the basic and mainstay method in management of atrial fibrillation.This method classically includes 3 aspects of rate control,rhythm control and anti-coagulation.In order to control symptoms as well as complicated heart failure and stroke,rational and standardized use,and combination of medications are paramount.The new classification of the disease,some tricky points in electrocardiographic diagnosis,and comparison between American stroke risk score CHADS2 and European CHA2DS2VASc are important points to be studied so that the choice of drug use or other advanced therapies can be optimized.
出处 《医学综述》 2012年第16期2596-2599,共4页 Medical Recapitulate
关键词 心房颤动 药物治疗 分类 室率和节律控制 抗凝 Atrial fibrillation Drug therapy Classification Rate and rhythm control Anti-coagulation
  • 相关文献

参考文献15

  • 1Fuster V,Rydén LE,Cannom DS,et al.2011 ACCF/AHA/HRSfocused updates incorporated into the ACC/AHA/ESC 2006 guide-lines for the management of patients with atrial fibrillation:a report.
  • 2Camm AJ,Kirchhof P,Lip GY,et al.Guidelines for the manage-ment of atrial fibrillation:the Task Force for the Management of At-rial Fibrillation of the European Society of Cardiology(E.
  • 3Israel CW,Gronefeld G,Ehrlich JR,et al.Long-term risk of recur-rent atrial fibrillation as documented by an implantable monitoringdevice:implications for optimal patient care[J].J Am.
  • 4Bogun F,Anh D,Kalahasty G,et al.Misdiagnosis of atrial fibrilla-tion and its clinical consequences[J].Am J Med,2004,117(9):636-642.
  • 5Snow V,Weiss KB,LeFevre M,et al.Management of newly detec-ted atrial fibrillation:a clinical practice guideline from the Ameri-can Academy of Family Physicians and the American Colleg.
  • 6Mounsey JP,DiMarco JP.Dofetilide[J].Circulation,2000,102(21):2665-2670.
  • 7Nutescu EA,Shapiro NL,Ibrahim S,et al.Warfarin and its interac-tions with foods,herbs and other dietary supplements[J].ExpertOpin Drug Saf,2006,5(3):433-451.
  • 8Feldstein AC,Smith DH,Perrin N,et al.Reducing warfarin medi-cation interactions:an interrupted time series evaluation[J].ArchIntern Med,2006,166(9):1009-1015.
  • 9Eikelboom JW,Wallentin L,Connolly SJ,et al.Risk of bleedingwith 2 doses of dabigatran compared with warfarin in older andyounger patients with atrial fibrillation:an analysis of the.
  • 10Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versuswarfarin in patients with atrial fibrillation[J].New Eng J of Med,2011,365(11):981-892.

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部